首页>
外国专利>
Allogeneic immunotherapeutic agent comprising three human prostate tumour cell lines derived from three different primary tumours useful in treating prostate cancer
Allogeneic immunotherapeutic agent comprising three human prostate tumour cell lines derived from three different primary tumours useful in treating prostate cancer
展开▼
机译:包含源自三种不同原发肿瘤的三种人前列腺肿瘤细胞系的同种异体免疫治疗剂,可用于治疗前列腺癌
展开▼
页面导航
摘要
著录项
相似文献
摘要
Disclosed is a product comprised of specific combinations of cell lines intended for use as an allogeneic immunotherapy agent for the treatment of prostate cancer in humans. The heterogeneity of the immunotherapeutic matches the heterogeneity of the antigenic profile in the target prostate cancer and immunises the recipients with many of the potential TAA and TSA which are expressed at various stages of the disease. Particularly disclosed is a vaccine comprising a combination of three different cell lines prepared from primary or metastatic prostate cancer biopsy material. The cell lines are lethally irradiated utilising gamma irradiation at 50-300 Gy to ensure that they are replication incompetent.
展开▼